in

Updated results of phase 1 study of bispecific teclistamab BCMAxCD3 show preliminary efficacy in patients with highly treated relapsed or refractory multiple myeloma

Updated results of phase 1 study of bispecific teclistamab BCMAxCD3 show preliminary efficacy in patients with highly treated relapsed or refractory multiple myeloma

Data from Pfizer / BioNTeh and Moderna for COVID-19 vaccines are “very robust”: European agency EMA

Weekly Unemployment Assistance Requests Rise in US